TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01091415

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: calcium phosphate bone cement injection
Description: volar locking plate alone versus calcium phosphate bone cement as well as volar locking plate
Study: NCT02688231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented upper limb training
Description: Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.~The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.~The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented upper limb training
Description: Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.~The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.~The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control intervention
Description: The participants in the control group receive for 8 weeks the conventional multidisciplinary rehabilitation program (physiotherapy, occupational therapy and speech or cognitive therapy if needed).~The training sessions are scheduled for 60 min/day, 5 days/week for the duration of 8 weeks.
Study: NCT01830101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ plus concurrent re-irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ plus concurrent re-irradiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: low-dose temozolomide daily for one year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: low-dose temozolomide daily for one year
Study: NCT04845555

Intervention type: OTHER
Intervention: Observation of the association between clotting factor level and risk of bleeding whilst physical activity
Description: The participants of this study will be monitored for a period of twelve months regarding individual clotting factor level, bleeding episodes as well as type and intensity of physical activity. By doing so, bleeding events, factor consumption as well as the course of the individual factor clotting factor level will be documented via the mobile application myPKFiT. This individual factor treatment regime will be compared with the retrospective treatment outcome in the last twelve months before the first study visit.
Study: NCT04016428

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OPTIMISM
Description: Six-week online program that emphasizes mindfulness and skills for improving sleep during pregnancy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education
Description: Six-week online program that provides education on sleep during pregnancy.
Study: NCT01585207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vigabatrin
Description: 3 tablets, bid for 8 weeks
Study: NCT05325268

Intervention type: PROCEDURE
Intervention: Osteosynthesis
Description: Treatment of fracture with open reduction and osteosynthesis
Study: NCT04492696

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education
Study: NCT03601585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison of dental biofilm removal.
Description: Comparison of the use of 4 methods for dental biofilm removal

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of dental biofilm removal.
Description: Comparison of the use of 4 methods for dental biofilm removal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison of dental biofilm removal.
Description: Comparison of the use of 4 methods for dental biofilm removal

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Comparison of dental biofilm removal.
Description: Comparison of the use of 4 methods for dental biofilm removal
Study: NCT01507662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bone Mineral Density Result Letter and Bone Health Brochure
Description: Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
Study: NCT02034513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin degludec
Description: Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin aspart
Description: Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
Study: NCT03347019

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation
Description: advances in arthroscopic surgery have resulted in biomechanically stronger repairs that might allow for accelerated rehabilitation protocols and hence faster return to daily living activities and scapular control

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Delayed rehabilitation
Description: Patients were not allowed to start rehabilitation programme first three weeks after surgery.
Study: NCT01159873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-37251
Description: up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
Study: NCT02386358

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benznidazole
Description: Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo at a dose 5 m/Kg/day until 60 days
Study: NCT01731977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-based family psychoeducation
Description: Family psychoeducation in a group setting is performed every two weeks for eight weeks.
Study: NCT03192813

Intervention type: DEVICE
Intervention: Symetis ACURATE neo™ transfemoral TAVI system
Description: Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).

Intervention type: DEVICE
Intervention: Medtronic CoreValve Evolut R TAVI System
Description: Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
Study: NCT01020825

Intervention type: DRUG
Intervention: ASCs
Description: Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.

Intervention type: DRUG
Intervention: Fibrin glue
Description: After curettage, the fistulous tract was sealed with fibrin glue.

Intervention type: DRUG
Intervention: ASCs
Description: Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
Study: NCT03355261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: complete remission (CR) group
Description: According to the RECIST 1.1, 32 patients were allocated into the complete remission (CR) group based on their responses to neoadjuvant chemotherapy (NAC).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: partial remission (PR) group
Description: According to the RECIST 1.1, 61 patients were allocated into the partial remission (PR) group based on their responses to neoadjuvant chemotherapy (NAC).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: stable disease (SD) group
Description: According to the RECIST 1.1, 12 patients were allocated into the stable disease (SD) group based on their responses to neoadjuvant chemotherapy (NAC).
Study: NCT02752854

Intervention type: OTHER
Intervention: pain threshold measurement
Description: pressure algometer
Study: NCT03355261

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: progressive disease (PD) group
Description: According to the RECIST 1.1, 5 patients were allocated into the progressive disease (PD) group based on their responses to neoadjuvant chemotherapy (NAC).
Study: NCT05296655

Intervention type: OTHER
Intervention: Reflux Symptom Index Inventory (diagnostic survey)
Description: Kazakh versions of the Reflux Symptom Index Inventory will be filled patients

Intervention type: OTHER
Intervention: Reflux Symptom Index Inventory (diagnostic survey)
Description: Kazakh versions of the Reflux Symptom Index Inventory will be filled patients

Intervention type: OTHER
Intervention: Reflux finding score
Description: laryngoscopy with a score RFS
Study: NCT04695782

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil beam proton radiotherapy
Description: Doseescalated pencil beam proton Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Pencil beam proton radiotherapy
Description: Doseescalated pencil beam proton Therapy
Study: NCT02579551

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical excision
Study: NCT03497286

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-based mentorship
Description: The treatment is a text-based peer-to-peer mentorship program for new mothers to promote the healthy development of young children by enhancing the parenting skills of the children's parents. Volunteer mentors who are experienced parents are paired with the parents of newborns. Mentors use text messaging to communicate with, support and encourage new parents while providing best-practice information, answers to the parents' questions, suggestions regarding activities to foster healthy development, and reminders about key milestone activities. The typical NurturePA mentor-mother pair communicates back-and-forth multiple times per week, at any time of the day.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control text messaging
Description: Control participants will receive periodic texts from NurturePA with information about child safety and health.
Study: NCT02284854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 2-093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Study: NCT03881878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAHP and AHP
Description: (A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with pCR:D1 X 11-12 cycles, q3weeks~* Atezolizumab (1200mg, IV)~* Trastuzumab (600mg, SC)~* Pertuzumab (420mg, IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAHP plus AC and AHP
Description: (A, Neoadjuvant setting): D1 X 6 cycles, q3weeks~* Docetaxel (75mg/m2, IV)~* Atezolizumab (1200mg, IV)~* Tastuzumab (600mg, SC)~* Pertuzumab (840mg loading dose at Cycle 1 followed by 420mg, IV)~(B, Adjuvant setting) : patients with non-pCR~* Doxorubicin(60mg/m2) plus cyclophosphamide (600mg/m2) D1 X 4cycles q3weeks followed by~* Atezolizumab (1200mg, IV), Trastuzumab (600mg, SC) and Pertuzumab (420mg, IV) D1 X 11-12 cycles q3weeks
Study: NCT00921544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sucrose
Description: 0.2 ml sucrose 24% given by mouth using a syringe and pacifier

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water
Description: Sterile water administered 2 mins prior to eye exam
Study: NCT03346746

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Diet
Description: This intervention was a diet that provided participants with three meals with a low GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Glycaemic Diet
Description: This intervention was a diet that provided participants with three meals with a high GI value. These meals were breakfast (9am), lunch (midday) and a snack (3pm).
Study: NCT02553473

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Study: NCT02865824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continue thienopyridine
Description: Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Discontinue thienopyridine
Description: Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
Study: NCT03922750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin icodec
Description: Participants will receive subcutaneous (s.c.) injections of Insulin 287 OW for 16 weeks.
Study: NCT02553473

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03706066

Intervention type: DEVICE
Intervention: Acrysof IQ PanOptix IOL
Description: Single-piece, ultraviolet and blue-light filtering, foldable, multifocal intraocular lens (IOL) inserted into the capsular bag during cataract surgery

Intervention type: PROCEDURE
Intervention: Cataract surgery
Description: Per investigator's standard of care
Study: NCT02363426

Intervention type: DEVICE
Group type: OTHER
Intervention: INVOcell Culture Device
Description: INVOcell is a vaginal culture device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVF Incubation
Description: IVF Incubator
Study: NCT00724035

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
Study: NCT03412552

Intervention type: DRUG
Intervention: MgSO4
Description: Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip

Intervention type: DRUG
Intervention: MgSO4
Description: Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip

Intervention type: DRUG
Intervention: MgSO4
Description: Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip

Intervention type: DRUG
Intervention: MgSO4
Description: Loading dose of magensium sulphate (4-6g I.V), given over 20 minutes in 100 ml of dextrose, Maintenance dose (4-6g) magensium sulphate in 500 cc dextrose given over 8 hours using continuous IV drip
Study: NCT01518036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 2.9 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somatropin
Description: 4.3 IU/m\^2/day. Administered as once daily subcutaneous injection until final height is reached
Study: NCT05299957

Intervention type: DIAGNOSTIC_TEST
Intervention: PETMRI
Description: PET/MRI data will be acquired on the integrated PET/MRI scanner. After fast-view T1-weighted MR localizer sequence for scout imaging and Dixon VIBE sequence for attenuation correction, a whole-body PET scan will be performed to cover from the head to the proximal thigh, with an acquisition time of 4 min per bed position. Simultaneously, whole body MR image acquisition will be performed with the axial HASTE sequence and coronal STIR sequence as well as the sagittal T1-weighted Turbo spine echo and STIR sequence. Afterwards, regional PET and MRI images will be simultaneously performed. DWI will be performed using a single shot spin-echo echo-planar technique. A total of 10 b values will be used for the reconstruction of IVIM and kurtosis imaging. DCE-PWI will be acquired by using a 3D T1-weighted spoiled gradient-echo sequence. Thereafter, dedicated regional MRI will be obtained. Finally, whole body axial VIBE with fat saturation will be performed.
Study: NCT01140932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: 12 days of corticosteroids treatment (prednisolone 37,5 mg/day)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle change
Description: High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)
Study: NCT03021005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIV Self-testing
Study: NCT04298112

Intervention type: DIAGNOSTIC_TEST
Intervention: PSMA PET/CT
Description: Whole-body PET/CT (contrast enhanced CT or low-dose CT); from vertex to thighs.

Intervention type: DIAGNOSTIC_TEST
Intervention: PSMA PET/MR
Description: Pelvic PET/MR in addition to targeted PET/MR according to other findings from the PET/CT (e.g. columna)
Study: NCT02595879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Undergo LDR brachytherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FDG-PET/CT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo pelvic EBRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Undergo FDG-PET/CT
Study: NCT00724035

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary brachial plexus nerve block
Description: Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.~A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infraclavicular brachial plexus block
Description: Blocks will be performed under high-resolution real-time ultrasound guidance.~Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.~The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks.
Study: NCT04183257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral vitamin D
Description: oral Vitamin D 400IU will be given and will be escalated every 2 weeks.
Study: NCT03661541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squaric Acid Dibutyl Ester
Description: 2% squaric acid dibutyl ester (SADBE) (Supplied by Squarex) is topically applied to the inner aspect of the upper arm of the subject and covered with Tegaderm. Subject is advised to wash it off after 3 hours.